Please login to the form below

Not currently logged in
Email:
Password:

Takeda considers India deals, says report

India's the Economic Times has reported that Takeda is holding talks with India-based generic drug firms Cipla and Lupin

Takeda Pharmaceutical Company is reportedly in takeover talks with India-based generic drug manufacturers Cipla and Lupin, according to the Economic Times.

Takeda, which has said it wants to expand in India, one of the world's fastest growing drug markets, has reportedly held preliminary talks with Cipla, while talks with Lupin have progressed beyond the initial stage.

The newspaper, which cited individuals with direct knowledge of the development, could not confirm the story with official representatives of the companies. It did, however, quote a Cipla spokeswoman: "We would like to clarify that these reports are baseless and untrue and is categorically denied."

The Economic Times said that Takeda was interested in buying Lupin's domestic formulations business, as well as its research facility, but its founders were not willing to sell the research unit.

The speculation follows news that Sanofi is to expand its role in India with the acquisition of Universal Healthcare's over-the-counter business unit.

For more information about the fast-growing pharmaceutical industry in India, see PMGroup's Country Report: India.

24th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics